Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2026, titled "Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS in the U.S., Significantly Expanding its Innovative Portfolio. RYALTRIS is Glenmark s first innovative product introduced into the U.S. market".

Glenmark Pharmaceuticals Inc., USA announced it will now manage end-to-end commercialization and distribution of RYALTRIS® nasal spray in the United States, effective April 1, 2026. RYALTRIS® is an FDA-approved fixed-dose combination nasal spray for Seasonal Allergic Rhinitis containing olopatadine hydrochloride and mometasone furoate. The product was initially launched in the U.S. in 2022 through a different distribution model. With this shift, Glenmark will directly handle brand strategy, market access, and customer engagement, allowing for greater operational control and responsiveness in the U.S. market. This is Glenmark's first innovative product introduced into the U.S. market and represents a significant step in building a direct commercial presence in the region. The product is approved in multiple markets including the U.S., EU, UK, Australia, South Korea, Russia, and China, and was launched in 11 additional markets in FY26.